Status:
UNKNOWN
Efficacy and Safety of Hemoperfusion or Plasma Exchange Compared to Standard Medical Therapy in Patients With Acute on Chronic Liver Failure
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Acute-On-Chronic Liver Failure
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The study is done with the aim of finding the association between the bilirubin and bile acids / DAMPS molecule with organ failures and sepsis in the patients with acute on chronic liver failure . in ...
Eligibility Criteria
Inclusion
- Patients diagnosed with ACLF as per APASL criteria will be included.
- Age : 18-65 yrs.
Exclusion
- Patient with ischemic heart disease
- Patient with chronic obstructive disease.
- Patient with hepato cellular carcinoma.
- Patient with extra hepatic malignancy.
- Patient with chronic renal insufficiency.
Key Trial Info
Start Date :
July 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2020
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04013113
Start Date
July 9 2019
End Date
July 31 2020
Last Update
July 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India, 110070